sl-172154
sl-172154: sourced relationships with 1 company · 1 clinical trial tracked.
sl-172154 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could sl-172154 → STTK affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Shattuck Labs, Inc. (STTK) | Phase 1 |
Clinical Trial Registry Records (1)
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Primary endpoint: Safety Profile of SL-172154 Monotherapy or in Combination With Azacitidine
Frequently asked questions
Which companies have sourced relationships with sl-172154?
sl-172154 has dated SEC/FDA relationship records for Shattuck Labs, Inc..
How many clinical trials involve sl-172154?
BioSniper tracks 1 clinical trial involving sl-172154.